Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.47 |
| ▸ | PARP1 | P09874 | 4/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15537421 | 0.93 | HTR2C (0.56) | SLC6A2SLC6A4HTR2CSLC6A3PARP1 | |
| SCHEMBL15380385 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A4HTR2CSLC6A3PARP1 | |
| SCHEMBL15378065 | 0.84 | PARP1 (0.42) | HTR2CPARP1 | |
| SCHEMBL17868818 | 0.83 | PARP1 (0.46) | SLC6A2SLC6A4HTR2CSLC6A3PARP1 | |
| SCHEMBL17868817 | 0.80 | HTR2C (0.47) | SLC6A2SLC6A4HTR2CSLC6A3PARP1 | |
| SCHEMBL15537425 | 0.79 | HTR2C (0.48) | SLC6A2SLC6A4HTR2CSLC6A3PARP1 | |
| SCHEMBL22611747 | 0.78 | PARP1 (0.48) | SLC6A2SLC6A4SLC6A3PARP1KCNH2 | |
| SCHEMBL14869717 | 0.78 | PARP1 (0.54) | SLC6A2SLC6A4SLC6A3PARP1CYP2D6 | |
| SCHEMBL5968190 | 0.78 | PARP1 (0.54) | SLC6A2SLC6A4SLC6A3PARP1CYP2D6 | |
| SCHEMBL5330092 | 0.78 | PARP1 (0.54) | SLC6A2SLC6A4SLC6A3PARP1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193723-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130303508-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303508-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | SLC6A2 920/4885SLC6A4 1993/4885HTR2C 4198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.